Study Summaries
ACTION Trial - Early Stage Ovarian 10 year
Completeness of surgical staging is a significant prognostic factor, with better outcomes observed in optimally staged patients. Adjuvant chemotherapy benefits appear restricted to nonoptimally staged patients.
Tisotumab in Cervical Cancer: InnovaTV 204/ GOG-3023/ENGOT-cx6 Phase 2 trial
Tisotumab vedotin showed clinically meaningful and durable antitumor activity with a manageable and tolerable safety profile in women with previously treated recurrent or metastatic cervical cancer.
GOG 240: Bevacizumab in Advanced Cervical Cancer
The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer improved median overall survival by 3.7 months and was associated with higher response rates.
Tata Memorial Hospital Trial: Neoadjuvant Chemo + Surgery vs. ChemoRT
Cisplatin-based concomitant chemoradiation resulted in superior DFS compared to neoadjuvant chemotherapy followed by radical surgery in patients with locally advanced cervical cancer.
UTERUS-11: Surgical versus clinical staging before primary chemoradiation
GROINS V II: Radiotherapy Versus Inguinofemoral Lymphadenectomy
Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, showing minimal morbidity. However, for patients with SN macrometastasis, radiotherapy alone resulted in more isolated groin recurrences compared to IFL.
GOG 92: Sedlis Criteria Study
Adjuvant pelvic radiotherapy significantly reduces the risk of cancer recurrence in women with Stage IB cervical cancer who have undergone radical hysterectomy and pelvic lymphadenectomy and possess specific high-risk factors. The treatment is associated with higher but acceptable morbidity.
SIENDO Trial: Selinexor in TP53wt Advanced or Recurrent Endometrial Cancer
Landoni Trial: Radical Surgery versus Radiotherapy for Stage Ib-IIa Cervical Cancer
There is no clear treatment of choice for early-stage cervical carcinoma in terms of overall or disease-free survival. Treatment should be tailored to individual patient factors such as menopausal status, age, medical conditions, histological type, and cervical diameter to achieve the best outcomes